India as Early-Phase Clinical Trials Destination: The Case Global Sponsors Are Missing

India has long been recognised as a preferred destination for Phase III clinical trials. What is less widely understood is that it has quietly become an increasingly compelling destination for early-phase clinical trials—Phase I and II studies — and that the regulatory and operational environment behind this shift has matured substantially.

The New Drugs and Clinical Trials Rules, 2019 (NDCT Rules) restructured India’s clinical trial framework, introducing defined regulatory review timelines, mandatory ethics committee accreditation, and stronger sponsor accountability. CDSCO has since released a draft GCP revision built on ICH E6(R3), incorporating risk-based quality management, e-consent, and decentralised-trial provisions. Combined with a growing pool of GCP-trained investigators, well-established medical institutions, and significant genetic and demographic diversity, India’s early-phase proposition deserves serious strategic consideration from global sponsors.

The Regulatory Framework for Early-Phase Clinical Trials

For most of the last two decades, India’s exclusion from early-phase programmes was largely a function of regulatory design — the requirement to complete Phase I elsewhere before Indian sites could participate removed India from first-in-human programmes at the architectural stage. That structural barrier no longer exists.

The most consequential change is permission for simultaneous global Phase I enrolment. Sponsors can now include Indian sites in a single global FIH protocol from the outset, without completing Phase I in another jurisdiction first. This repositions India from a sequential add-on market into a legitimate co-participant in early global development timelines.

For investigational drugs already approved in recognised Stringent Regulatory Authority (SRA) jurisdictions — US FDA, EMA, MHRA — CDSCO applies an expedited 30-day review timeline. This directly addresses the open-ended regulatory uncertainty that has historically complicated Indian site inclusion.

The CDSCO Ethics Committee registration framework under the NDCT Rules creates a centrally maintained, verifiable list of compliant ECs. Registration is a regulatory prerequisite, not a voluntary quality mark, giving sponsors a defensible foundation for site selection decisions.

Finally, CDSCO’s provision allowing waiver of local clinical trial data — applicable where robust global data exists — signals a deliberate regulatory orientation: India is positioning itself as a participant in global development, not a separate market requiring standalone evidence. Taken together, these provisions constitute a coherent regulatory architecture that makes early-phase participation structurally viable in a way it has not been before.

India vs. Competing Early-Phase Trials Destinations

When compared honestly against alternatives, India’s position is stronger than its historical underrepresentation suggests.

Patient Enrolment Speed:

India’s 1.4 billion population, high burden of treatment-naïve patients, and concentration of large tertiary care centres create conditions for rapid enrolment. China offers comparable speed but faces growing pressure on investigator bandwidth from surging domestic trial activity. Eastern Europe delivers reliable execution but from meaningfully smaller patient pools.

Regulatory Timeline:

India’s 30-day expedited review for SRA-approved drugs removes timeline uncertainty that has historically been difficult to model. China’s timelines have improved but remain variable; Eastern Europe presents a fragmented picture with significant country-by-country variation.

Cost:

India’s operating costs run approximately 50–60% below comparable Western programmes — the largest differential of any competing destination. China’s savings of 40–55% are being compressed by rising site infrastructure costs. Eastern Europe offers 30–45% savings, the smallest margin and trending upward.

Genetic Diversity:

South Asian populations carry distinct genetic variants affecting drug metabolism, disease susceptibility, and therapeutic response that are not adequately represented in data from Caucasian or East Asian cohorts. For sponsors developing products for global populations, early-phase trial data generated exclusively from Western or East Asian sites carries known blind spots. Indian sites offer the opportunity to surface pharmacokinetic signals in South Asian populations at the stage when that information is most actionable.

English-Language Operations:

India’s English-language clinical and regulatory environment means protocols, consent documents, CRFs, and regulatory submissions require no translation. For China, translation is a non-negotiable requirement at every stage. For Eastern Europe, English proficiency varies by country and investigator. India removes this friction entirely.

No competing destination matches India’s combination of enrolment depth, a defined regulatory pathway, the largest cost differential, unique genetic representation, and frictionless English-language operations.

Disease Areas of Strategic Strength

Oncology:

India carries a substantial and distinctive oncology burden — head and neck, cervical, and gastrointestinal cancers present at high volumes with an epidemiological profile meaningfully different from Western cancer populations. A significant proportion of patients at major oncology centres are treatment-naïve, directly benefiting FIH and dose-escalation studies where prior treatment history affects eligibility and signal detection.

Cardiovascular and Metabolic Disease:

India has one of the largest and fastest growing cardiometabolic disease populations globally, with type 2 diabetes, hypertension, and coronary artery disease presenting at younger ages and lower BMIs than in Western populations. This phenotypic pattern has significant implications for pharmacological research and addresses a demographic that is simultaneously underrepresented in existing datasets and overrepresented in global disease burden.

Infectious Disease:

India offers direct, high-volume patient access across infectious diseases that remain major global health challenges — tuberculosis (including drug-resistant strains), hepatitis B and C, dengue, and typhoid — accessible through established units at major academic and public health institutions. For sponsors developing novel anti-infectives, Indian sites are in many cases the only sites capable of generating the required patient-level data.

Central Nervous System:

Epilepsy affects an estimated 10–12 million people in India. Schizophrenia and treatment-resistant depression carry significant prevalence and unmet need. The investigator base has matured alongside this burden, with several institutions developing dedicated CNS research units capable of meeting the protocol complexity and safety monitoring demands that early-phase CNS studies require.

Respiratory Disease:

India’s respiratory disease population is large and clinically heterogeneous, driven by genetic predisposition, occupational exposures, biomass fuel use, and urban air quality — producing a patient profile meaningfully different from the atopic, smoking-related disease that dominates Western trial populations. For sponsors developing inhaled therapies or novel COPD mechanisms, Indian populations offer both volume and phenotypic diversity.

Addressing Common Sponsor Concerns In Early-Phase Clinical Research

Data Quality and Regulatory Acceptability:

Indian clinical trials conducted under the NDCT Rules and ICH E6 GCP standards generate data accepted by the FDA, EMA, and other ICH member regulators. Indian site data has featured in successful regulatory submissions across multiple therapeutic areas. The operative question is not whether Indian data is acceptable in principle — it is whether specific sites are operating to the required standard. That is a site qualification question, not a jurisdiction question.

Intellectual Property Protection:

India’s patent framework has been significantly strengthened since the Patents (Amendment) Act 2005, bringing it into closer TRIPS alignment. Clinical trial data confidentiality is protected under Indian law. Sponsors operating on IP assumptions formed a decade or more ago are applying an outdated risk assessment to a materially different legal context. As with any jurisdiction, appropriate contractual precautions and India-specific legal counsel are advisable — but the categorical IP concern that once carried real weight no longer reflects the actual operating environment.

Operational Complexity:

Of the three concerns, operational complexity is the most legitimate — and the most manageable. Import licensing for IMPs, EC processes, site activation timelines, and cold-chain logistics all require competent local management. But this complexity is characteristic of any non-domestic jurisdiction and is substantially mitigated by working with CROs and regulatory partners with ground-level Indian experience. The infrastructure for well-managed early-phase work exists and is mature at the top tier of Indian sites. Sponsors who have worked through the operational learning curve consistently report that it is steeper in anticipation than in execution.

Conclusion

India has firmly established itself as a compelling destination for early-phase clinical trials, offering a mature ecosystem that balances cost-efficiency with high-quality, globally acceptable data. By integrating Indian clinical sites into multinational programs, sponsors can achieve faster patient recruitment, diverse demographic representation, and strong regulatory acceptability with CDSCO and international authorities.

CliniExperts Research serves as your premier India-based CRO, delivering end-to-end clinical trial solutions through:

Strategic Regulatory Submissions: Expert CDSCO filings, CTA preparation, and compliance with the latest Drugs and Cosmetics Rules.
Advanced Site Selection: Data-driven site identification and qualification with rapid activation capabilities.
Ethics Committee Liaison: Proactive coordination for swift EC approvals and ongoing GCP compliance.
Comprehensive Clinical Trial Management: Full-scope study oversight from protocol execution to final reporting.